-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Presidential Symposium

Program: General Sessions
Tuesday, December 8, 2015: 9:45 AM-11:15 AM
Hall D, Level 2 (Orange County Convention Center)

Lecture Title:
Hematologic Diseases in the Post-Genome Era: New Insights, New Therapies, New Possibilities

David A. Williams, MD, President, American Society of Hematology, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Harvard Medical School

No relevant conflicts of interest to declare.

The past decade of scientific investigation has led to new understanding of somatic genome mutations and their role in hematologic diseases, as well as important insights into the role of germline mutations and epigenetic drivers of cancers such as leukemia. In each of these areas, the relative pristine genomes of pediatric cancers and the successes in treating monogenic diseases in children with genetically modified cells and targeting the epigenome have yielded insights and tools that have and will be used in adult diseases. During the 2015 ASH Presidential Symposium, three experts will discuss the insights gained in the study of childhood diseases and their impact on evolving therapies for adult hematologic disorders.

Dr. Mignon Loh will describe how germline and somatic mutations in juvenile myelomonocytic leukemia have led to new understanding of the evolution of this disease and have provided insights into the complexity of targeting RAS-mutated leukemias.

Dr. Scott Armstrong will discuss how the understanding of epigenetic lesions in infant and childhood acute leukemias is leading to new therapeutic approaches in both pediatric and adult leukemia.

Dr. Luigi Naldini will discuss how nearly 20 years of research in gene therapy has set the stage for gene replacement and editing in pediatric monogenic diseases, such as primary immunodeficiencies and storage diseases, and will lead the way to new therapies for adult hematologic diseases.

Mignon L. Loh, MD

Department of Pediatrics, Benioff Children’s Hospital, University of California at San Francisco, San Francisco, CA

Scott A. Armstrong, MD, PhD

Memorial Sloan-Kettering Cancer Center, New York, NY

Luigi Naldini, MD, PhD

San Raffaele University, San Raffaele Telethon Institute for Gene Therapy, Milan, Italy

See more of: General Sessions